Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCL-2510
- Development stage
- Phase 1
- Lead developer
- Vical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
VCL-2510 is a plasmid DNA vaccine encoding the gene for the malaria circumsporozoite protein from *Plasmodium falciparum* (PfCSP). It is designed to induce immune responses against malaria by targeting the liver stages of the parasite. The vaccine is administered intramuscularly and has been tested for safety and immunogenicity in clinical trials.
- Other names
- PfCSP DNA vaccine
02
Targets
CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on VCL-2510.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCL-2510.